Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 2/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | ANXA2 | P07355 | 2/20 | 0.39 |
| ▸ | S100A10 | P60903 | 2/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.35 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.35 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.35 |
| ▸ | TGM2 | P21980 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2978805 | 0.82 | ALDH1A1 (0.42) | SRD5A2ALDH1A1LMNA | |
| SCHEMBL2717446 | 0.78 | SRD5A2 (0.41) | SRD5A2CES2CES1ANXA2S100A10 | |
| SCHEMBL2969264 | 0.78 | THRB (0.48) | ALDH1A1LMNA | |
| SCHEMBL28040263 | 0.74 | SMN1; SMN2 (0.48) | ALDH1A1 | |
| SCHEMBL2718721 | 0.73 | LDHA (0.44) | SRD5A2CES2CES1ANXA2S100A10 | |
| SCHEMBL2720653 | 0.70 | SRD5A2 (0.41) | SRD5A2CES2CES1ANXA2S100A10 | |
| SCHEMBL24335762 | 0.70 | LTA4H (0.40) | HIF1AALDH1A1LMNA | |
| SCHEMBL13205914 | 0.69 | HDAC1 (0.41) | SRD5A2TGM2 | |
| SCHEMBL26134135 | 0.69 | TEAD1 (0.49) | — | |
| SCHEMBL648641 | 0.67 | SRD5A2 (0.83) | SRD5A2CES2CES1PTPN1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286144-A1 | HETEROARYL DERIVATIVES | TAKAHASHI YOKO | 2010-11-11 | — | — | US | disclosed |
| US-7781479-B2 | Heteroaryl derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-08-24 | — | — | US | disclosed |
| US-20080167306-A1 | Novel Heteroaryl Derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-07-10 | — | — | US | disclosed |
| EP-1837329-A1 | NOVEL HETEROARYL DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2007-09-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286144-A1 | HETEROARYL DERIVATIVES | GPR119, SLC2A1, SLC2A4 | SRD5A2 110/4885CES2 473/4885CES1 28/4885 |
| US-20080167306-A1 | Novel Heteroaryl Derivative | GPR119, SLC2A4, SLC5A2 | SRD5A2 133/4885CES2 428/4885CES1 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.